The Use of Rheumatic Disease Comorbidity Index for Predicting Clinical Response and Retention Rate in a Cohort of Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Alpha Inhibitors

Table 2

Baseline prevalence of comorbidities.

Comorbidity, n (%)	Overall; n = 346	TNFis			Concomitant MTX
		ADA	ETN	P	No	Yes	P
		n = 172	n = 174		n = 157	n = 189
Osteoporosis	85 (24.6)	41 (23.8)	44 (25.3)	0.803	45 (28.6)	40 (21.1)	0.132
Hypertension	72 (20.8)	33 (19.2)	39 (22.4)	0.509	37 (23.6)	35 (18.5)	0.288
Depression	39 (11.3)	25 (14.5)	14 (8)	0.063	13 (8.3)	26 (13.7)	0.126
Cardiovascular disease	36 (10.4)	17 (9.9)	19 (10.9)	0.861	15 (9.6)	21 (11.1)	0.725
Lung disease	26 (7.5)	11 (6.4)	15 (8.6)	0.542	12 (7.6)	14 (7.4)	1
Fibromyalgia	25 (7.2)	12 (7)	13 (7.5)	1	8 (5.1)	17 (9)	0.211
Autoimmune thyroid disease	19 (5.5)	8 (4.6)	11 (6.3)	0.638	12 (7.6)	7 (3.7)	0.154
Dyslipidemia	19 (5.5)	5 (2.9)	14 (8)	0.057	7 (4.4)	12 (6.3)	0.486
Diabetes	12 (3.5)	6 (3.5)	6 (3.4)	1	4 (2.5)	8 (4.2)	0.558
Gastrointestinal disorders	10 (2.9)	5 (2.9)	5 (2.9)	1	6 (3.8)	4 (2.1)	0.522
Osteoporotic fractures	8 (2.3)	5 (2.9)	3 (1.7)	0.501	6 (3.8)	2 (1.1)	0.148
Neurological disorders	6 (1.7)	1 (0.6)	5 (2.9)	0.215	1 (0.6)	5 (2.6)	0.227
History of malignancy	1 (0.3)	0 (0)	1 (0.6)	1	0 (0)	1 (0.5)	1

ADA: adalimumab; ETN: etanercept; MTX: methotrexate; TNFis: tumor necrosis factor alpha inhibitors.